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Abstract
In a variety of cancers, altered patterns of microRNA (miRNA) expression are reported and may affect the cell cycle and 
cell survival. Recent studies suggest that the expression level of miRNAs that act as tumor suppressors is frequently 
reduced in cancers because of chromosome deletions, epigenetical changes, aberrant transcription and disturbances 
in miRNA processing. miR-143 and -145, which are located approximately 1.3 kb from each other at chromosome 5q33, 
are highly expressed in several tissues, but down-regulated in most cancers. However, the mechanism of this down-
regulation has not been investigated in detail. Here, we show that both miRNAs were expressed well under the same 
control program in human tissues, but were down-regulated equally in the most of the cancer cell lines tested. Then 
we identified the host gene encoding both miRNAs. The transcripts of this gene were approximately 11, 7.5, and 5.5 kb 
long; and the expression of these transcripts was coordinated with that of its resident miRNAs and down-regulated in 
the cancer cell lines tested as well as in colorectal cancer tissue samples. These data demonstrate that the host gene 
can function as a primary miRNA transcript and suggest that the down-regulation of host gene expression caused the 
low-expression of its encoded microRNAs-143 and -145 in human cancer cell lines and in cancer tissues.
Findings
MicroRNAs (miRNAs) are tiny, endogenously expressed
noncoding RNAs (18-25 nucleotides in length) that act as
crucial posttranscriptional regulators of gene expression
[1-3]. For several miRNAs, their participation in essential
biological processes has been proved, such as in cell pro-
liferation control, cell lineage fate decision, cell survival,
tissue patterning for development, and cell metabolism
[4]. Cancer is a very complex genetic disease character-
ized by alterations in genes encoding oncogenic and
tumor-suppressor proteins [5]. Recently, it has been
noted that the expression profiles of miRNAs can be used
for classification, diagnosis, and prognosis of human
malignancies; and the deletion or amplification of the
locus encoding an miRNA in a variety of cancers has
been reported. Altered patterns of miRNA expression
may affect cell-cycle and survival programs and be
involved in tumor initiation and progression. We previ-
ously found that microRNA-143  (miR-143) and -145
(miR-145) were down-regulated in colon cancers [6,7],
gastric cancers [8], chronic lymphocytic leukemias, and B
cell lymphomas [9], and in several human cancer cell lines
[7]. Several groups also reported the down-regulation of
both of these miRNAs in many other types of cancers,
such as bladder cancers and their cell lines [10,11], cervi-
cal cancers and their cell lines [12], colorectal cancers
[13-16], nasopharyngeal carcinoma [17], and prostate
cancer [18]. Furthermore, such abnormal expression was
found not only in malignant cells but also in cells in pre-
malignant stages such as colon adenoma cells [13,19].
The introduction of the mature type of either miR-143 or
-145 into colon cancer cells [6,7,20], B cell lymphoma [9],
and gastric cancer cells [8,21] results in a significant
growth inhibition that occurs in a dose-dependent man-
ner; and the target genes, ERK5 [22] and KRAS [20] for
miR-143 and IRS-1 [23] and c-myc [21] for miR-145, were
posttranscriptionally down-regulated. Taken together,
these findings suggest that miR-143  and -145  act as
tumor suppressors and provide an important clue in the
study of the mechanism of tumor initiation and progres-
sion involving miRNAs.
In the present study, we identified non-coding RNAs
carrying an miR-143  and -145  cluster (NCR143/145:
Non-coding RNA encoding miR-143/145) and investi-
gated the expression of NCR143/145  in all cancer cell
lines tested. Importantly, the down-regulation of this host
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gene expression caused the low expression of both miR-
NAs in human cancer cell lines, which could lead to
tumor development and progression.
Expression of miR-143 and -145
We examined the expression levels of mature miR-143
and -145 in human normal tissues by performing Taq-
Man microRNA assays (Fig. 1). In human normal tissues,
miR-143 and -145 showed good expression in stomach,
intestine, cervix, uterus, colon, and prostate (Fig. 1A, B).
Whereas, in cancer cell lines, they were expressed at an
extremely low level compared with that in human normal
cell lines (Additional file 1 - Figure S1). Compared with
their expression in corresponding normal tissues, the
expression levels of both miRNAs were obviously down-
regulated in all cancer cell lines and cancer tissue samples
tested, just as many groups had previously reported [6-
18]. Such a similar expression pattern of them indicates
that the expression of both miRNAs may be regulated by
a similar mechanism. Additionally, the DNA loci of both
miRNAs are very close to each other, within 1.3 kb, which
led us to speculate that both precursors may originate
from the same primary transcript. Genomic PCR span-
ning this region demonstrates the fragment in most of the
cancer cell lines tested [6,7,9]. Therefore, we decided to
isolate the gene that carried both miRNAs in a cluster.
Identification of non-coding RNA carrying the miR-
143/145 cluster
First, we carried out RT-PCR and inverted PCR cloning
method using human placenta and uterus cDNA, and a
placental cDNA library, and isolated each of the cDNA
clones designated in Figure 2. The 143-145 clone was 2.2
kb long and detected in human tissues such as uterus,
prostate, and testis by RT-PCR (data not shown). The
iPCR145 clone, which encoded miR-145, was 1.7 kb long
and corresponded to the transcriptional unit for only
miR-145 identified by Sachdeva [21] and Xu [24]. Clone
41 was 373 bp long (Fig. 2B) and amplified at a high level
in human normal tissues by semi-qRT-PCR, but hardly
amplified in several cancer cell lines examined (data not
shown). Clone AK126481 was 3.8 kb long and identical to
AK126481 in GeneBank, and clone AKF1-10 was 1.8 kb
long and overlapped with AK126481. Clone 4-35 was 129
bp long and contained a part of the predicted first exon
and novel second exon (Fig. 2A). At the upstream of this
predicted first exon, hypothetical transcriptional start
site was localized, which was shown by Fujita [25]. Also,
the homolog of this gene (IE 1071) and promoter region
were cloned in the mouse by Ebisuya [26] and shown to
be comparatively conserved between human and mouse.
This indicates that the predicted transcriptional start site
near the sequence of clone 4-35 is a putative promoter
region of the miR-143 and -145-encoding gene.
Next, we performed Northern blot analysis to look for
the transcripts that originated from the host gene encod-
ing miR-143 and -145. The large transcript (11 kb: open
arrow) and 3 or 4 transcripts (7.5, 5.5, and 1.9 kb: closed
arrows) were detected (Fig. 3). The 11-kb transcript was
hybridized with 6 probes (Fig. 2, a-f; Fig. 3), and the 1.9-
kb one was only detected by 143-145 (Fig. 3) and
iPCR145 probes (data not shown), and not detected by
the 4-35, 41, AKF1-10 or AK126481 probes (data not
shown). These results indicate that the host gene was
firstly transcribed into the 11-kb transcript and then pro-
cessed to the mature miR-143 and -145 via 7.5 and 5.5 kb
processed variant transcripts. This gene is the non-cod-
ing RNA shown by Ebisuya to be subject to splicing [26].
Also, in human normal tissues, miR-145 was consistently
expressed at higher levels than miR-143  (Fig. 1A, B).
Apart from both miRNAs being produced from the 11-kb
transcript,  miR-145  would also be generated from the
Figure 1 Real-time RT-PCR analysis of mature miR-143 and -145 
expression in human normal tissues. Total RNAs from human nor-
mal tissues were purchased from Biochain (Hayward, USA) and Takara 
(Otsu, Japan). Expression of both miRNAs in each sample was detected 
by using a TaqMan microRNA reverse transcription kit and TaqMan mi-
croRNA Assay Kit (Applied Biosystems, Foster City, USA) and normal-
ized with RNU6B. Calculation of the Ct value was done by using the 
second derivative maximum method, and relative quantification was 
analyzed by the comparative Ct (ΔCt) method. All reactions were run 
in triplicate. Relative miR-143 (A) and -145(B) expression levels (value of 
2-ΔCt(miR-RNU6B)) are indicated on the left axis, with error bars indicating 
the standard deviation for these analyses.
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Figure 2 Identification and characterization of the host gene encoding miR-143 and -145. (A) Scheme of the cytogenetic map of chromosomal 
region 5q33. RT-PCR cloning was performed by using the primer sets (B) that covered the predicted first exon-containing region (clone4-35;a) of 
LOC728264 [GeneBank:NR027180], predicted intron-spanning region (clone41;b), both miR-143 and -145 regions (143-145;c), predicted pre-miR-145 
region (iPCR145;d), AKF1-10 region (e), and AK126481 region (GeneBank;f) from human placenta and uterus cDNA, and cDNA library. The positions of 
neighboring genes, PCYOX1L, IL17B, CSNK1A1, and FLJ41603 are also shown as references. The real-time RT-PCR primer sets (LOC3 and 10) specific for 
this gene are indicated by the arrowheads. The open box (E') represents a novel exon derived from a cDNA clone (a). This exon is not shown in the 
NCBI database. Region "A" is a cardiac-specific enhancer reported by Cordes [29], and region "B" is p53 and/or Oct4-dependent miR-145 specific pro-
moter reported by Sachdeva [21] and Xu [24].
A
Genome
miR-143 miR-145
PCYOX1L IL17B LOC728264 CSNK1A1 FLJ41603
5q33
LOC3 primer
(a)
(b)
(c)
(d)
E’
(A) (B)
(e)
B
Forward primer Reverse primer
(a) clone4-35 5’-CCCAACCACTCCCCAAACAGGCTGG-3’  5’-TTACAGCCGTTGCTCTCCTT-3’
(b) clone41 5’-GCCATGCTGATGTCAGAGAA-3’  5’-GATCCCCAGTCAGGATGAGA-3’
(c) 143-145 5’-TTGGTCCTGGGTGCTCAAAT-3’  5’-TTTCCCAAGAGTACGGCAGT-3’
(d) iPCR145 5’-GAATCCCCATCTTAGCATCTAAGGGATT-3’ 5’-CTGGAAATACTGTTCTTGAGGTCATGGT-3’
(e) AKF1-10 5'-GGCCATAGACCCCTCTTCTCAGTAA-3' 5'-CTCGTGCATTTGGCTGGGGAGTGATTC-3'
(f) AK126481 5'-GCTCAGTGCCAGCTGCTTAAAAAT-3' 5'-TAGTCCTGGGCAGACCAGTTTCTATC-3'
LOC3 5’-GACCAGACCCCAGGAAAGA-3’ 5’-TTACAGCCGTTGCTCTCCTT-3’
LOC10 5'-AGCAAGAACTCTGGAGAAGCA-3' 5'-GAGAGGCGTGGGTGAGAG-3'
GAPDH(for real-time) 5’-CCACATCGCTCAGACACCAT-3’ 5’-GCAACAATATCCACTTTACCAGAGTTAA-3’
GAPDH( for cloning) 5'-CCACCCATGGCAAATTCCATGGCA 5'-TCTAGACGGCAGGTCAGGTCCACC-3'
(f)
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Figure 3 Northern blot analysis of the host gene encoding miR-143 and -145. Total RNAs (5 μg for human normal tissues, cancer tissue, and can-
cer cell lines [human stomach tumor RNA was purchased from Takara]) were separated on a 1%(w/v) formaldehyde agarose gel and then blotted onto 
Hybond N+ nylon membranes (Amersham Biosciences, Piscataway, USA). RNA probes were synthesized from template cDNAs by using a MAXIscript 
kit (Ambion, Austin, USA) incorporating Digoxigenin-11-UTP (Roche, Penzberg, Germany). Northern blots were hybridized with the AKF1-10 clone (A, 
upper panel; refer to Fig. 2), 143-145 clone (A, 2nd panel), GAPDH (A, 3rd panel; B, middle panel), and 28 S rRNA (A and B, under panel). The primary 
transcript is marked by the open arrow and other transcripts are marked by closed arrows.
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1.9-kb transcript. It is thought that this expression of
miR-145 is regulated by a different mechanism depen-
dent on p53 [21] and/or Oct4 [24]. In our preliminary
experiments, the expression of host gene and its pro-
moter activity were p53-independent in p53-mutated
cancer cell lines (MKN-45 and DLD-1, data not shown).
This finding of p53 independency raises the possibility
that p53-dependent gene expression and other pathways
are abrogated in p53-mutated cancer cell lines. We are
currently investigated this point in our laboratory.
Regulation of NCR143/145 expression in cancers
Most miRNAs located within protein-coding or non-cod-
ing genes are transcriptionally linked to the expression of
their host genes [27]. In order to investigate the coordi-
nated expression of the host gene identified in this study
with mature miR-143 and -145, we performed real-time
RT-PCR analysis by using the host gene-specific primer
set shown in Fig. 2. In human normal tissues, the host
gene was highly expressed, as were both miRNAs; but in
the corresponding cancer cell lines, the signal was hardly
detected (Fig. 4A), though the host gene and both miR-
NAs were highly expressed in normal human cell lines
(Additional files 1 - Figure S1 & S2). Also in human can-
cer tissues, the host gene was down-regulated compared
with its expression in normal human tissues (Figs. 3, 4B
and additional file 1 - Figure S3). As a result, the down-
regulation of host gene NCR143/145 expression caused
low expression of both mature miRNAs in human cancer
cell lines. Thus, the aberrant transcription of NCR143/
145 could contribute to the low expression of miR-143
and -145.
The expression level of miRNAs that act as tumor sup-
pressors is frequently reduced in cancers because of chro-
mosome deletions, epigenetical changes, aberrant
transcription, and disturbances in miRNA processing.
Michael et al. [13] reported that in colorectal cancers the
decreased levels of mature miR-143 and -145 were due to
reduced  Dicer-processing activities. In our study, the
activity and expression of Dicer  and  RISC  proteins
seemed to be intact in colorectal cancer cells, because the
expression levels of miR-143 and -145 were up-regulated
by stimulation with a growth inhibitor [7]. Therefore, we
propose that the inadequate expression of miR-143 and -
145 was due to the perturbation of transcription and/or
that of the another processing enzyme, Drosha, which
causes the transit from primary miRNAs to precursor
ones. Recently, it was reported that p53 interacts with the
Drosha  processing complex through association with
DDX5 and facilitates the processing of primary miRNAs
to precursor ones [28]. That report also indicated that
mutant  p53  interfered with these processing activities.
These findings suggest that the inappropriate p53-depen-
dent modulation of miRNA biogenesis also affects the
expression of mature miRNAs in cancer cells. But, in our
study,  Drosha  expression and its processing activity
seemed to be normal in p53-mutated MKN-45 and K562
cells (data not shown).
To exclude the possibility that the DNA of the loci and
histone were epigenetically methylated, in earlier studies
[6,7,9] we examined by qRT-PCR the expression of both
miRNAs in DLD-1, SW480 and EBV-transformed L25
cells after treatment of the cells with 5-aza-2'-deoxycyti-
dine and tricostatin A. As a result, the levels of both miR-
NAs were almost unchanged by either treatment [6,7,9].
Figure 4 Real-time RT-PCR analysis of the host gene encoding 
miR-143 and -145. Real-time RT-PCR analysis was performed on hu-
man normal tissues and cancer cell lines (A) and human colon adeno-
carcinoma samples (B) by using host gene-specific primers. Ten pairs 
of colon samples, including 10 human colon adenocarcinoma tissue 
samples and 10 matched normal colon tissue samples, were obtained 
from Osaka Medical College Hospital (Takatsuki, Osaka, Japan) and Fu-
jita Health University Hospital (Toyoake, Aichi, Japan) with patients' in-
formed consent. Collection and distribution of the samples were 
approved by each of the appropriate institutional review boards. The 
category of colon samples was confirmed by pathological analysis. To-
tal RNA was extracted from the colon samples by using TRIzol (Invitro-
gen, Carlsbad, USA) according to the manufacturer's protocol. 
Expression levels of the host gene in each sample (LOC3 and LOC10, 
refer to Fig. 2) were detected by using a Superscript III reverse tran-
scription kit (Invitrogen, Carlsbad, USA) and SYBR Premix Ex Taq (Taka-
ra, Otsu, Japan) and normalized with GAPDH. Ruled lines present the 
medians of samples. Data were analyzed by using Student's t-test. A 
value of p < 0.05 was considered significant.
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To confirm the presence of the genomic locus including
b o t h  m i R N A s  a t  c h r o m o s o m e  5 q 3 3 ,  w e  c a r r i e d  o u t
genomic PCR on several cancer cell lines (Additional file
1 - figure S4) [6,7,9]. In HeLa, U937, and PC3 cells, one
allele of the locus might have been deleted. This locus is
frequently involved in chromosome copy number loss in
various types of cancers including non-small cell lung
cancer and gastric cancer according to the CGH database
http://www.cghtmd.jp/CGHDatabase/index_j.jsp. There-
fore, further detailed cytogenetic study will be needed to
understand the mechanism of miR-143 and -145 down-
regulation in many cancer cell lines.
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